ATARA BIOTHERAPEUTICS, INC. License Costs (Deprecated 2018-01-31)
ATARA BIOTHERAPEUTICS, INC. (ATRA) reported License Costs (Deprecated 2018-01-31) of $4.50 million for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LicenseCosts · last filed 2017-11-09
- ATARA BIOTHERAPEUTICS, INC. license costs (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $0.00.
- ATARA BIOTHERAPEUTICS, INC. license costs (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $0.00.
- ATARA BIOTHERAPEUTICS, INC. license costs (deprecated 2018-01-31) for the quarter ending 2017-03-31 was $4.50M, a 0.00% change year-over-year.
- ATARA BIOTHERAPEUTICS, INC. license costs (deprecated 2018-01-31) for the quarter ending 2016-12-31 was $0.00.
- ATARA BIOTHERAPEUTICS, INC. license costs (deprecated 2018-01-31) for fiscal 2016 was $4.50M, a 0.00% change from fiscal 2015.
- ATARA BIOTHERAPEUTICS, INC. license costs (deprecated 2018-01-31) for fiscal 2015 was $4.50M.
| Period end | License Costs (Deprecated 2018-01-31) 0 month | License Costs (Deprecated 2018-01-31) 3 month | License Costs (Deprecated 2018-01-31) 6 month | License Costs (Deprecated 2018-01-31) 9 month | License Costs (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|---|
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $0.00 derived: sum of 2 quarters · filed 2017-11-09 | $4.50M 10-Q · filed 2017-11-09 | $4.50M derived: sum of 4 quarters · filed 2017-11-09 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $4.50M 10-Q · filed 2017-08-07 | $4.50M derived: sum of 3 quarters · filed 2017-08-07 | $4.50M derived: sum of 4 quarters · filed 2017-08-07 | |
| 2017-03-31 | $4.50M 10-Q · filed 2017-05-04 | $4.50M derived: sum of 2 quarters · filed 2017-05-04 | $4.50M derived: sum of 3 quarters · filed 2017-05-04 | $4.50M derived: sum of 4 quarters · filed 2017-05-04 | |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09 | $0.00 derived: sum of 2 quarters · filed 2017-03-09 | $0.00 derived: sum of 3 quarters · filed 2017-03-09 | $4.50M 10-K · filed 2017-03-09 | |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $0.00 derived: sum of 2 quarters · filed 2016-11-04 | $4.50M 10-Q · filed 2016-11-04 | ||
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $4.50M 10-Q · filed 2016-08-08 | |||
| 2016-03-31 | $4.50M 10-Q · filed 2016-05-06 | ||||
| 2015-12-31 | $4.50M 10-K · filed 2016-03-04 | ||||
| 2012-09-30 | $250.00K 10-Q · filed 2014-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |